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Abstract
Purpose The goal of this guideline/procedure standard is to assist nuclear medicine physicians, other nuclear medicine
professionals, oncologists or other medical specialists for recommended use of [ 18F]FDG PET/CT in oncological patients
undergoing immunotherapy, with special focus on response assessment in solid tumors.
Methods In a cooperative effort between the EANM, the SNMMI and the ANZSNM, clinical indications, recommended
imaging procedures and reporting standards have been agreed upon and summarized in this joint guideline/procedure
standard.
Conclusions The field of immuno-oncology is rapidly evolving, and this guideline/procedure standard should not be seen as
definitive, but rather as a guidance document standardizing the use and interpretation of [18F]FDG PET/CT during immunotherapy. Local variations to this guideline should be taken into consideration.
Preamble The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association founded
in 1985 to facilitate worldwide communication among individuals pursuing clinical and academic excellence in nuclear
medicine. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional
organization founded in 1954 to promote science, technology and practical application of nuclear medicine. The Australian
and New Zealand Society of Nuclear Medicine (ANZSNM), founded in 1969, represents the major professional society
fostering the technical and professional development of nuclear medicine practice across Australia and New Zealand. It
promotes excellence in the nuclear medicine profession through education, research and a commitment to the highest professional standards. EANM, SNMMI and ANZSNM members are physicians, technologists, physicists and scientists specialized in the research and clinical practice of nuclear medicine. All three societies will periodically put forth new standards/
guidelines for nuclear medicine practice to help advance the science of nuclear medicine and improve service to patients.
Existing standards/guidelines will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner,
if indicated. Each standard/guideline, representing a policy statement by the EANM/SNMMI/ANZSNM, has undergone a
thorough consensus process, entailing extensive review. These societies recognize that the safe and effective use of diagnostic nuclear medicine imaging requires particular training and skills, as described in each document. These standards/
guidelines are educational tools designed to assist practitioners in providing appropriate and effective nuclear medicine care
for patients. These guidelines are consensus documents based on current knowledge. They are not intended to be inflexible
rules or requirements of practice, nor should they be used to establish a legal standard of care. For these reasons and those
set forth below, the EANM, SNMMI and ANZSNM caution against the use of these standards/guidelines in litigation in
which the clinical decisions of a practitioner are called into question. The ultimate judgment regarding the propriety of any
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specific procedure or course of action must be made by medical professionals considering the unique circumstances of each
case. Thus, there is no implication that an action differing from what is laid out in the guidelines/procedure standards, standing alone, is below standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action
different from that set forth in the standards/guidelines when, in the reasonable judgment of the practitioner, such course of
action is indicated by the condition of the patient, limitations of available resources or advances in knowledge or technology
subsequent to publication of the guidelines/procedure standards. The practice of medicine involves not only the science,
but also the art of dealing with the prevention, diagnosis, alleviation and treatment of disease. The variety and complexity
of human conditions make it impossible for general guidelines to consistently allow for an accurate diagnosis to be reached
or a particular treatment response to be predicted. Therefore, it should be recognized that adherence to these standards/
guidelines will not ensure a successful outcome. All that should be expected is that practitioners follow a reasonable course
of action, based on their level of training, current knowledge, clinical practice guidelines, available resources and the needs/
context of the patient being treated. The sole purpose of these guidelines is to assist practitioners in achieving this objective.
The present guideline/procedure standard was developed collaboratively by the EANM, the SNMMI and the ANZSNM,
with the support of international experts in the field. They summarize also the views of the Oncology and Theranostics and
the Inflammation and Infection Committees of the EANM, as well as the procedure standards committee of the SNMMI,
and reflect recommendations for which the EANM and SNMMI cannot be held responsible. The recommendations should
be taken into the context of good practice of nuclear medicine and do not substitute for national and international legal or
regulatory provisions.
Keywords Positron emission tomography · PET/CT · [18F]FDG · guideline · immunotherapy · treatment response ·
malignant tumors
Abbreviations
AI	Artificial Intelligence
ANZSNM	Australian and New Zealand Society of
Nuclear Medicine
BLR	Bone marrow-to-liver ratio
BRAF	B Rapidly Accelerated Fibrosarcoma
CMR	Complete metabolic response
cPMD	Confirmed progressive metabolic disease
CR	Complete response (anatomical)
ceCT	Contrast-enhanced CT
CT	Computed tomography
CTLA-4	Cytotoxic T-lymphocyte-associated protein
4
DR	Dissociated response
EANM	European Association of Nuclear Medicine
EARL	EANM Research Ltd
EGFR	Epidermal growth factor receptor
EORTC	European Organization for Research and
Treatment of Cancer
FD	Fractal dimension
FDG	2-[18F]fluoro-2-deoxy-D-glucose
HPD	Hyperprogressive disease
ICIs	Immune checkpoint inhibitors
IDDM	Insulin-Dependent Diabetes Mellitus
imPERCIST	Immunotherapy-modified PERCIST
irAEs	Immune-related adverse events
iRECIST	Modified RECIST 1.1 for immune-based
therapeutics
irRECIST	Immune-related Response Evaluation Criteria in Solid Tumors
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MDM 2/4	Murine double minute 2/4
MEK	Mitogen-activated protein kinase
MIP	Maximal intensity projection
MTV	Metabolic tumor volume
NSCLC	Non-small cell lung cancer
PECRIT	PET/CT Criteria for Early Prediction of
Response to Immune checkpoint inhibitor
Therapy
PERCIMT	PET Response Evaluation Criteria for
IMmunoTherapy
PERCIST	Positron Emission Tomography Response
Criteria In Solid Tumors
PD	Progressive disease
PD-1	Programmed cell death-associated protein 1
PD-L1	Programmed death ligand 1
PET/CT	Positron emission tomography/computed
tomography
PFS	Progression-free survival
PMD	Progressive metabolic disease
PMR	Partial metabolic response
PPD	Pseudoprogressive disease
PR	Partial response
QIBA	Quantitative Imaging Biomarkers Alliance
RECIST	Response Evaluation Criteria in Solid
Tumors
RSNA	Radiological Society of North America
SD	Stable disease
SLR	Spleen-to-liver ratio
SMD	Stable metabolic disease
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SNMMI	Society of Nuclear Medicine and Molecular
Imaging
SUL	Standardized uptake value normalized by
lean body mass
SUV	Standardized uptake value
TLG	Total lesion glycolysis
TMTV	Total metabolic tumor volume
TNM	Tumor (T), nodes (N), and metastases (M)
uPMD	Unconfirmed progressive metabolic disease
VOI	Volume of interest

Introduction
In the last decade, remarkable achievements in cancer
treatment were made with the introduction of the immune
checkpoint inhibitors (ICIs) [1, 2]. Most importantly, these
have included the development and clinical introduction
of antibodies against cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) and programmed cell death-associated
protein 1 (PD-1) and its ligand 1 (PD-L1). In 2011, ipilimumab, an anti-CTLA-4 monoclonal antibody, was the first
to be approved by regulatory authorities based on the significant improvement in overall survival in melanoma [2].
Swiftly, this was followed by the development of monoclonal antibodies targeting PD-1, such as pembrolizumab
and nivolumab, as well as those targeting PD-L1, such as
avelumab and atezolizumab [3–6]. These agents act at differing points in T-cell activation with anti-CTLA-4 antibodies affecting early T cell priming and anti-PD-1 and PD-L1
affecting T-cell proliferation and cancer cell killing [7]. They
can be used as single- or dual-agent therapies, or in combination with other standard oncological treatments including chemotherapy, radiotherapy or other targeted therapies
[8–12]. The rapidly expanded clinical use of ICIs in the
treatment of metastatic disease across a broad range of cancers was extended also to adjuvant and neoadjuvant settings
in combination with curative intent surgery or radiotherapy
of local or regional disease with a high risk of recurrence
[12–14]. While durable responses can be achieved in a subset of metastatic patients, growing evidence suggests greater
efficacy for these agents in the context of low tumor burden,
even when conventional imaging does not depict measurable
metastatic disease [15]. This is presumably achieved by targeting cancer cells before the development of an increasingly
unfavorable tumor microenvironment, which, in turn, results
in evolving resistance to immunotherapy treatments [16].
The immense progress of ICIs has brought challenges for
cancer management, including a need for the oncological
community to reconsider the conventional ways of assessing treatment efficacy and to develop strategies to manage a
variety of relatively common immune-related adverse events
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(irAEs) that are not often encountered with other cancer
therapies. It is now recognized that the effectiveness of ICIs
is contingent on the successful activation of the multi-step
cancer immunity cycle by the host immune cells. This begins
with antigen presentation to dendritic cells and subsequently
leads to priming, trafficking and infiltration of effector T
cells into the tumor microenvironment [17]. Beyond conventional patterns of response as seen in chemotherapy, in
a subset of patients unconventional modes of response were
noted with delayed apparent efficacy of ICIs. These included
a transient increase in tumor burden or even appearance of
new lesions, termed “pseudoprogression,” which were attributed to initial recruitment of immune cells at tumor sites
[18]. The standard radiographic criteria [19], commonly
used to evaluate responses to chemotherapies or targeted
therapies, did not account for these new kinetics of response.
Hence, several modified evaluation criteria were devised
to account for the appearance of new lesions and transient
size increase by an extended delay to prove or refute tumor
progression. These include immune-related response criteria (irRC) based on bidimensional measurements of target
lesions or unidimensional size evaluation such as immunerelated RECIST (irRECIST), immune RECIST (iRECIST)
and immune-modified RECIST (imRECIST) [18, 20–22].
Cancer cells utilize aerobic glycolysis in part to fuel cell
growth and energy needs [23], and this represents the fundamental pathway imaged by [ 18F]FDG PET/CT. Given the
complexity of various immunotherapeutic responses, which
challenged the conventional framework of RECIST, several
studies evaluated the utility of [ 18F]FDG PET/CT in monitoring the response to ICIs [24–33]. As with morphological imaging, mechanistic differences in the mode of action
of ICIs also challenged extrapolating the success of [ 18F]
FDG PET/CT in monitoring cytotoxic or targeted treatment
to evaluate immunotherapeutic strategies with checkpoint
inhibitors [34]. Indeed, the very same metabolic reprogramming used by cancer cells extends to T cells, as both cancer
cells and tumor infiltrating effector T cells possess highaffinity GLUT1 transporters to facilitate glycolysis [35]. This
leads to a complicated interpretation of [ 18F]FDG PET/CT,
especially early (in the first weeks/months) after treatment
initiation, since increasing metabolic activity during therapy
within the morphologically stable lesions paradoxically may
indicate recruitment and activation of immune cells into
the tumor microenvironment or draining lymphoid tissues
rather than progression. Beyond response monitoring, [ 18F]
FDG PET/CT has shown accuracy in monitoring systemic
immune response and detecting irAEs in an early stage.
PET/CT-derived quantitative metabolic parameters appeared
to have prognostic implications [34, 36–39]. Therefore, there
is an unprecedented need to provide imaging specialists
and clinicians with a clinical practice framework for a more
accurate, systematic and harmonized interpretation of [18F]
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Fig. 1  Illustration of four
specific patterns of response to
immunotherapy: a) pseudoprogression; b) hyperprogression;
c) dissociated response; d)
durable response

FDG PET/CT in the rapidly evolving era of immunotherapeutic strategies.

observed with conventional cytotoxic or targeted anticancer
treatments.

Pseudoprogressive disease

Goals
The goal of this guideline/procedure standard is to provide
nuclear medicine professionals recommendations to correctly perform, interpret and report the results of [18F]FDG
PET/CT in oncological patients undergoing immunotherapy,
with a special focus on response assessment in solid tumors.
In addition, it provides general information to other
professionals and medical specialties related to immuneoncology, i.e., radiologists, medical oncologists and radiation oncologists, for whom the acknowledgment of [18F]
FDG PET/CT applications in this clinical context can be
useful to support decisions regarding appropriate patient
management.
This field is rapidly evolving, and this guideline/procedure standard cannot be seen as definitive, nor is it a
summary of all existing protocols. Local variations to this
guideline should be taken into consideration within a multidisciplinary setting.

Historically, progressive disease is defined by an increase
in size of target or nontarget lesions or by the appearance
of new lesions (Fig. 1a). However, a series of clinical trials
evaluating the efficacy of ipilimumab in melanoma demonstrated an unconventional pattern of tumor response on conventional imaging with transitory anatomical “progression”
followed by response [41–43]. This pattern of response was
named pseudoprogressive disease (PPD), and new response
criteria were created [44, 45]. Most frequently, PPD occurs
within the first 4–6 weeks of treatment, but can also occur
up to several months after ICI initiation. The rate of PPD
varies between tumor types and immunotherapies and has
been reported in up to 10% of patients based on CT scan [46,
47] or [ 18F]FDG PET [48], appearing to be most common in
patients with metastatic melanoma treated with anti-CTLA-4
antibody [46, 47], especially with combined ICIs. The PPD
phenomenon has been attributed to a variety of mechanisms,
including a delayed activation of immune response, local
edema due to inflammatory processes and infiltration of
immune cells within tumor lesions [49].

Definitions

Dissociated response

Beyond the conventional imaging patterns of tumor
response, such as complete/partial response and stable
disease, ICIs have been associated with novel atypical patterns of response to treatment [40] that are not, or rarely,

Dissociated response (DR), also known as mixed response or
disproportional response (Fig. 1c), is defined by a decrease or
stabilization in some tumor sites with a concomitant increase
in other sites [50]. In patients treated with ICIs, DR has been
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reported in up to 10% of the cases [47, 48, 51]. A proportion
of patients in retrospective cohorts benefit from prolonging
ICI after a dissociated response, despite its classification as
true progression by conventional response criteria. Some
studies have demonstrated that a dissociated response is associated with a better prognosis than homogeneous progression
of lesions in patients treated with ICI [48, 52]. This pattern
of response may reflect the heterogeneity of tissue-specific
tumor microenvironments, and can be easily detected by [18F]
FDG PET due to its high sensitivity and capacity to assess
early response on a lesion-by-lesion basis. From a clinical
perspective, patients with dissociated response may benefit
from treatment beyond progression potentially by continuing
checkpoint inhibitor therapy and integrating local treatments,
such as surgery, radiotherapy or interventional radiological
treatment of oligoprogressive lesions [53].

Hyperprogressive disease
Hyperprogressive disease (HPD) is defined as an atypical
acceleration of tumor growth kinetics leading to premature
death (Fig. 1b), which may occur following immunotherapy treatment [54–56]. Between 4% [57] and 29% [58] of
patients with solid tumors will develop an augmented progression profile leading to a doubling of tumor burden and/
or a twofold increase in tumor growth rate during ICI. There
is currently no consensus on the precise criteria by which to
define HPD, since previous studies used different methods
of tumor burden assessment (for example, the sum of the
largest diameters, tumor volume measurement) and different
thresholds of tumor growth kinetics. In other cases, also a
time to treatment failure under 2 months has been used to
define HPD [57, 58]. Due to its recent emergence as a clinical phenomenon, HPD may be underdiagnosed. Therefore,
the underlying mechanism of development represents an
area of active investigation [59]. Some risk factors for HPD
have been, however, described, and they include higher age
[56] and the presence of MDM2/4 (murine double minute
2/4) family amplification or EGFR ( epidermal growth factor
receptor) aberrations [57].

Durable response
Depending on tumor and ICI type, 10 to 25% of patients
with metastatic cancer will achieve a durable tumor response
(Fig. 1d) that can be maintained several years even after stopping the treatment [60, 61]. A recent pooled analysis of phase
III trials found that the proportion of patients who experienced
a durable response was 2.3 times higher in those treated with
an ICI compared with those treated by standard chemo/targeted therapies in the control arms (25% vs 11%) [62]. There is
currently no standardized definition of durable response, since
the criteria of durable response differ across studies.
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Clinical indications
The use of [ 18F]FDG PET/CT in the context of immunotherapeutic regimens should be considered at various time
points related to treatment, based on clinical requirements.
In particular:
– Before start of treatment
	  At baseline, [ 18F]FDG PET/CT should be considered
mandatory for tumor assessment, for [18F]FDG-avid
tumors, particularly in case of first-line immunotherapeutic regimens, since it provides a basis for tumor
monitoring or a confirmation of disease progression/
recurrence.
	  Defining target lesions, the most intense sites of [ 18F]
FDG uptake (e.g., SUVmax, SUVpeak) and computation of volumetric parameters (e.g., MTV) are recommended at baseline, to act as a basis for monitoring disease response at a later time.
– During the course of treatment
	 [18F]FDG PET/CT is recommended at interim, commonly 8-12 weeks (i.e., 3-4 cycles) after treatment start,
in particular to complement the information obtained
from morphological imaging with CT and to resolve
discordant findings.
	  The PET/CT scan can be also performed earlier or
later during the course of treatment in case of clinical
deterioration and/or suspicious progression on contrastenhanced CT.
– Before immunotherapy discontinuation
	  In patients receiving maintenance therapy or undergoing long-term treatment with ICIs, [18F]FDG PET/CT
may be obtained to assess metabolic response, particularly in partial responders or stable disease on CT [63].
	  In patients requiring a temporary interruption of
immunotherapy, [18F]FDG PET/CT restaging is recommended before restarting the treatment to reestablish a
new baseline for subsequent response assessment.

Response criteria
A wide range of response criteria to ICI (Table 1) have been
proposed, typically relying on ceCT scans. Although these
criteria account for pseudoprogression, they do not encompass the complexity of managing patients with ICIs due to
several new patterns of response and progression described
below. In addition, a wide range of treatment combinations
is currently being explored. These extend from systemic
ICIs monotherapy to combinations with chemotherapy or
targeted therapies in cases with relevant tumor mutations
(e.g., BRAF/MEK in melanoma and EGFR in non-small cell
lung cancer, NSCLC). Other treatment variations include
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FDG PET
Undetermined
Minimum tumor SUL
1.5 × mean SUL liver,
≤ 5 target lesions/patient

FDG PET
Undetermined

Tumor lesion with the
highest SUV uptake

Modality
Delay for confirmation
of PMD
Target lesions
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Stable metabolic disease
(SMD)

Partial metabolic
response (PMR)

Disappearance of all
Complete resolution of
metabolically active
FDG uptake within the
lesions
tumor volume so that
it was indistinguishable from surrounding
normal tissue
A reduction of a
Reduction in sum of
minimum of 15–25%
SULpeak in target
in tumor SUV after one
lesions > 30% and absocycle of chemotherapy,
lute drop in SUL > 0.8
and > 25% after more
SUL units
than one treatment
cycle
Neither PMD, PMR, nor
An increase in
CMR
SUV < 25% or a
decrease < 15% and
no visible increase in
extent of FDG tumor
uptake (> 20% in the
longest dimension)

Complete metabolic
response (CMR)

Progression

Progression

New lesions

Wahl et al. [68]
2009
Solid tumors
Chemotherapy, targeted
therapies

Young et al. [67]
1999
Solid tumors
Chemotherapy

Reference
Year
Tumor
Treatment

PERCIST 1.0*

EORTC*

Criteria

Table 1  Immune-related response criteria: [18F]FDG PET

Disappearance of some
metabolically active
lesions without any
new lesion

Disappearance of all
metabolically active
lesions

Neither PMD, PMR, nor
Neither PD, PR or CR,
CMR
evaluation of change in
SUL peak of the hottest
lesion:
> 15.5% (clinical benefit),
≤ 15.5% (no clinical
benefit)

≥ 30% decrease from
baseline

Disappearance of all
lesions

Progression

Minimum tumor SUL
Size (metabolically
1.5 × mean SUL liver,
active lesion) > 1.0 or
≤ 5 target lesions/patient
1.5 cm,
≤ 5 target lesions/patient
Metabolic progressive
Immune unconfirmed
disease (PMD)
metabolic progressive
disease (iuPMD)

RECIST 1.1
PERCIST 1.0

Need to be included in the
sum of SULpeak,
PMD if > 30% increase in
sum of SULpeak
Disappearance of all metabolically active lesions

Minimum tumor SUL
1.5 × mean SUL liver,
≤ 5 target lesions/patient

FDG PET
3 months

Ito et al. [28]
2019
Melanoma
Immune checkpoints
inhibitors (anti-PD-1)

imPERCIST5

Neither PMD, PMR, nor
CMR

Neither PMD, PMR, nor
CMR

Reduction in SULpeak in Reduction in sum of
target lesions ≥ 30%
SULpeak in target
lesions ≥ 30% and absolute drop in SUL by ≥ 0.8
SUL units

Disappearance of any
uptake in target lesion

FDG PET
2 months

Goldfarb et al. [29]
2019
NSCLC
Immune checkpoints
inhibitors (anti-PD-1)

iPERCIST

Anwar et al. [26]
2018
Melanoma
Immune checkpoints
inhibitors (antiCTLA-4)
CT and FDG PET
3 months

PERCIMT

Cho et al. [24]
2017
Melanoma
Immune checkpoints
inhibitors (anti-PD-1,
anti-CTLA-4)
CT and FDG PET
3–4 weeks

PECRIT
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Confirmed PMD
(cPMD)

* Although originally developed for chemotherapy and targeted treatments, EORCT and PERCIST criteria can be used even in case of immunotherapeutic regimens

na
PET at 4–8 weeks: confirmed PMD
na
na
na

> 30% increase in
SULpeak, with > 0.8 SUL
unit increase in tumor
SULpeak
≥ 30% increase in
SULpeak or new metabolically active lesions:
immune unconfirmed
PMD (iuPMD)
≥ 4 new lesions
of < 1 cm or ≥ 3 new
lesions of > 1 cm or
≥ 2 new lesions
of > 1,5 cm

An increase in
SUV > 25% within the
tumor region defined
on the baseline scan,
visible increase in the
extent FDG tumor
uptake (> 20% in the
longest dimension) or
the appearance of new
FDG uptake in metastatic lesions
na
Progressive metabolic
disease (PMD)

≥ 20% increase in the
Increase in sum of
nadir of the sum of tarSULpeak of > 30% or
the appearance of a new get lesions (> 5 mm)
lesion

imPERCIST5
iPERCIST
EORTC*
Criteria

Table 1  (continued)

PERCIST 1.0*

PECRIT

PERCIMT

European Journal of Nuclear Medicine and Molecular Imaging (2022) 49:2323–2341

2329

localized delivery of ICIs through intraarterial perfusion,
local treatments with intratumoral immunotherapy [64] and
radiotherapy–immunotherapy combinations [65, 66].
At a clinical trial level, it has been demonstrated that
reclassifying pseudoprogressive patients as treatmentsensitive avoids a potential bias that would otherwise favor
chemotherapeutic alternatives based on progression-free survival (PFS), when, in fact, such patients may subsequently
achieve prolonged survival. This phenomenon led to the
refinement of standard response evaluation guidelines in
the form of irRC [22], iRECIST [21] and irRECIST [69]
for solid tumors. To prevent patients with PPD from prematurely terminating treatment, these guidelines propose a
“wait-and-see” strategy (reevaluation using a follow-up scan
4–8 weeks later), when tumor burden appears to increase on
imaging without significant clinical deterioration.
The interpretation of [18F]FDG PET/CT in patients
treated with immunotherapy has to take into account this
PPD phenomenon. Hence, several metabolic response criteria have been proposed as an alternative to PERCIST criteria [68]. These criteria are summarized below. Currently,
there are insufficient data to decide which of these different
approaches to categorize response is preferable. Furthermore, the impact on long-term patient outcomes has not
been prospectively validated in randomized clinical trials.
In advanced melanoma treated with ICIs, PET/CT Criteria for Early Prediction of Response to Immune checkpoint
inhibitor Therapy (PECRIT), which combines morphological (RECIST) and metabolic criteria, categorized 20 patients
on the presence or absence of clinical benefit with a 100%
sensitivity and a 93% specificity [24].
In an attempt to tackle the pitfalls and limitations of [ 18F]
FDG PET imaging—foremost the phenomenon of pseudoprogression—in the assessment of immunotherapy response
in melanoma, another set of modified response criteria has
been developed, the PET Response Evaluation Criteria for
IMmunoTherapy (PERCIMT). The cornerstone of PERCIMT is the finding that the changes in the absolute number
of [18F]FDG-avid lesions are more predictive of clinical outcome than their respective standardized uptake value (SUV)
changes during therapy with ICIs [26]. More specifically,
according to these criteria, neither a mere increase in SUV
of the target/index lesion(s) nor the development of one new
hypermetabolic lesion in follow-up [18F]FDG PET/CT scan
mean disease progression per se, as suggested by the conventional PERCIST/EORTC criteria [67, 68]. Instead, the
application of a threshold of four newly emerged, [ 18F]FDGavid lesions—with a decreasing cutoff of lesion number as
the functional diameter of the lesions increases—can more
correctly classify patients with progressive disease. More
specifically, PMD is determined as the appearance of either
four or more new lesions < 1 cm in functional diameter, or
three or more new lesions > 1.0 cm in functional diameter,
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or two or more new lesions > 1.5 cm in functional diameter [26]. Otherwise, the patient can be classified as in PPD
(Table 1).
PERCIMT criteria were developed in a metastatic melanoma cohort of 41 patients treated with ipilimumab, undergoing [18F]FDG PET/CT imaging before and after the end
of ipilimumab treatment, and using the patients’ clinical
response as reference [26]. They have been further validated
in melanoma cohorts under different immunotherapeutic
regimens and combinations both early during treatment
(after two cycles of ICIs) [70, 71] and at the end of it (four
cycles of ipilimumab and ipilimumab/vemurafenib treatment) [72, 73] yielding a satisfactory preliminary performance in patient stratification, predominantly in comparison
with EORTC. However, further evaluation of the newly proposed criteria in larger patient cohorts is warranted, preferably in correlation with other metabolic or volumetric [18F]
FDG parameters, such as MTV and total lesion glycolysis
(TLG), as well as clinical and laboratory data.
Derived from PERCIST, imPERCIST differs in that the
appearance of new lesions is not sufficient to classify a patient
as having progressive disease. In these criteria, the peak
standardized uptake value normalized for lean body mass
(SULpeak) of up to five lesions on the baseline and follow-up
scan is summed for each scan (maximum of 2 per organ). Target lesions on follow-up scans are the most intense lesions and
are not necessarily the same as target lesions at baseline. PMD
is defined as an increase of the sum of SULpeak by at least
30%. The appearance of new lesions is not sufficient to define
PMD, but new lesions are included in the sum of SULpeak
only if they show higher uptake than preexisting target lesions
or if fewer than five target lesions were detected on the baseline scan. The prognostic value of imPERCIST criteria slightly
outperformed those of standard PERCIST criteria [28].
Finally, a few recent studies have chosen to adapt the
PERCIST criteria to the “wait-and-see” approach initially
proposed by the iRECIST guidelines, leading to the socalled iPERCIST criteria [29, 48, 74]. Patients with new
lesions or increase of more than 30% of the sum of SULpeak
or of the SULpeak of the most intense lesions are classified as having unconfirmed progressive metabolic disease
(uPMD). Then, if patients are clinically stable, reevaluation
4 to 8 weeks later is needed to establish confirmed progressive metabolic disease (cPMD). These studies have found
that, for patients with metastatic lung cancer having uPMD
on the first interim PET, the subsequent confirmatory PET
reclassifies around one-third of these early-progressing
patients as patients with atypical response patterns (PPD or
dissociated response) who will in fact benefit from continuation of ICIs. Thus, it underlines the risk of falsely concluding
to treatment failure after a first uPMD, a risk that is higher
with [18F]FDG PET/CT than with ceCT due to its high sensitivity in detecting immune cell activation.
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As general recommendation from this guideline/procedure standard, in case doubts exist between progression or
pseudoprogression, especially on the first post-treatment
evaluation, a confirmatory follow-up [18F]FDG PET/CT
study 4–8 weeks later in the setting of clinical stability
should be performed (Figs. 2 and 3). This consensus stems
from the fact that there is no robust and externally validated tool to differentiate true progression from pseudoprogression based upon a single imaging assessment. Hence,
treatment should be continued in clinically stable patients,
absent excessive toxicity, to avoid discontinuation of ICIs
in patients who may exhibit clinical benefit and objective
response at a later time point.

Assessing immune organs and irAEs
In addition to the [18F]FDG PET/CT response criteria cited
above, that were created to meet the challenges raised by
immunotherapy, several groups have reported baseline prognostic factors of response such as the MTV [76] and uptake
in immune organs [77].
The first sign of immune activity to be evaluated is spleen
enlargement and/or increased uptake leading to an equalization or an inversion of the spleen-to-liver ratio (SLR) [39,
78]. Some groups also proposed other signs such as the bone
marrow-to-liver ratio (BLR) [79] and uptake in the ileocecal valve [80]. While the attention of the PET community
has been mainly focused on the capability of SLR to predict immune activation [34, 78] (an increased spleen uptake
being considered to reflect “unleashed” T lymphocytes
with an expected better outcome), several studies (Table 2)
showed that an increase in SLR on baseline or follow-up
[18F]FDG PET was an unfavorable finding, likely related to
inflammation and tumor burden.
Strong reproducibility was reported for spleen and bone
marrow measurements [81].
In addition to signs of immune activation and conventional or ICI-adapted [18F]FDG PET response criteria, the
third cornerstone is evaluating the occurrence of irAEs.
While several studies have shown that patients experiencing irAEs may have better survival [86, 87], studies on PETdetected irAEs are scarce [88, 89]. Lang et al. observed in a
melanoma cohort under ipilimumab a significant correlation
between PET signs of colitis and clinically significant diarrhea, although neither PET-colitis nor diarrhea was significantly correlated with response to therapy [90]. Recently,
Wong et al. showed that [18F]FDG PET/CT could often
detect relevant irAEs which may precede clinical diagnosis
in melanoma patients receiving a combination of two ICIs
(Table 3) [39, 91].
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Fig. 2  Illustration of target selection and [18F]FDG PET/CT response
evaluation in a patient with multiple lesions and a dissociated
response. Serial [18F]FDG MIP in a 73-year-old woman affected by a
metastatic melanoma of the anal canal. (a) PET baseline before introduction of immunotherapy and (b) after six courses of nivolumab,
showing a dissociated response with (i) progression of the main liver
lesion, (ii) good response in the largest nodal lesion (right pulmonary
hilum) and (iii) appearance of new lesions (liver, thoracic node, vertebral bone lesion; green arrows). This appearance of new lesions classifies the patient with progressive metabolic disease (PMD) according
to the PERCIST criteria. As opposed to PERCIST, in imPERCIST5
(immunotherapy-modified PERCIST, five-lesion analysis), the

appearance of new lesions alone does not result in PMD: PMD is
defined only by an increase of the sum of SULpeaks by 30%, and
new lesions are included in the sum of SULpeak if they show higher
uptake than existing target lesions or if fewer than five target lesions
were detected on the baseline scan. In the present case, a mediastinal node and a new bone lesion (green arrows) are selected, together
with the three preexisting lesions (panel b). The patient is also classified as PMD according to imPERCIST. Follow-up scans at 1 and 4
months show clear progression (c). Summary table of target lesions,
SULpeak values and their variation according to imPERCIST5 criteria are shown in panel (d)

[18F]PET/CT protocols

the vertex through the feet, can be indicated in case of neoplasia with clinical suspicion of more extensive metastatic
disease (e.g., NSCLC, melanoma, Merkel cell tumor, etc.).
[18F]FDG PET/CT with diagnostic CT and/or contrastenhancement can be used following the acquisition parameters determined according to specific radiological society
guidelines [98, 102].
In case of repeated [18F]FDG PET/CT, especially in
case of therapy response assessment, the scan should be
performed with identical acquisition and reconstruction
parameters, by maintaining stringent uptake intervals from
tracer administration to image acquisition. In case of facilities with multiple tomographs, the repeated scan should be
performed on the same machine. In any case, all scanners
should comply with international harmonizing standards,
such as the EANM/EARL program [98, 103].

[18F]FDG PET/CT Acquisition
[ 18F]FDG PET/CT procedure should be performed as
described in the EANM guideline [98] and SNMMI procedure standards for tumor imaging [99]. The RSNA QIBA
FDG/CT guidance is largely concordant and also acceptable
[100].
Briefly, fasting is recommended for at least 6 h, and
the acquisition should be performed following an interval
of 60 min from tracer injection (acceptable range of 55
– 75 min) [101] by using as default mode a torso imaging (from the skull base to the mid-thighs). Including the
skull base at least for therapy assessment examinations is
recommended, so that immune-related hypophysitis can be
detected. An extended whole-body imaging, covering from
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Fig. 3  PERCIST, iPERCIST, imPERCIST and PERCIMT evaluation
in a patient with pseudoprogression at early evaluation. Serial [18F]
FDG MIP in a 66-year-old woman affected by a metastatic cutaneous
melanoma. (a, b) MIP and transaxial slices at baseline before introduction of immunotherapy and after two courses of nivolumab (c-f),
showing two new lung lesions (d, f; green arrows) as well as a progression in tracer uptake and RECIST measurements of the main lung
metastasis (e; red arrows). This pattern classifies the patient with progressive metabolic disease (PMD) according to the PERCIST criteria,
and uPMD based on iPERCIST criteria. imPERCIST including the
two hottest lung lesions (e, f) also classifies the patient as PMD, due
to an increase in the sum of SULpeak greater than 30%. According to

PERCIMT, the patient is classified as SMD (appearance of two new
lesions, the size of which is <1.5 cm). Follow-up scan shows complete disappearance of lung lesions, classifying the patient as CMR
and retrospectively the early evaluation as pseudoprogression. Also
noteworthy is the appearance of a diffuse colic uptake suggestive of
colitis, confirmed also by wall thickening that is usually detected on
CT images (g) and serves for the differential diagnosis between metformin-induced colon uptake from immune-related colitis [75]. This
patient had a 23-month progression-free survival (PFS) and experienced a recurrence in the peritoneum and right adrenal gland with no
active disease at the thoracic level

Data extraction and analysis

same method should be used to evaluate all scans—baseline
and subsequent scans—in a patient as variability in MTV
determinations by varying methods is well known.
Use of quantitative [ 18F]FDG PET/CT parameters for
therapy monitoring purposes requires that these parameters
are comparable among patients, regardless of the PET/CT
system used. Therapy response criteria using SUVmax and,
to a lesser extent, SUVpeak are affected by reconstruction
inconsistencies between baseline and post-treatment scans
[106, 107], which may arise when scanning patients in centers running several PET systems or as a result of patients’
mobility requiring scans at a different facility. Delineation
of MTVs may be affected by the same errors as for SUVs,
with variability in tumor delineation methodology being
one of the major sources of variability [108]. It is therefore
recommended to comply with harmonizing standards such

Quantitative PET/CT can be used as a diagnostic or prognostic tool (i.e., single measurement) or for therapy monitoring (i.e., longitudinal studies). Metrics include standardized uptake value (peak or max) computed either using
bodyweight (SUV) or lean body mass (SUL) as normalizing measure for distribution volume, metabolic tumor
volume (MTV) and total lesion glycolysis (TLG), defined
as MTV × SUVmean. MTV is the volume inside a user- or
algorithm-defined volume of interest (VOI) used to circumscribe the metabolically active tumor. Several techniques
have been proposed to determine the limits of the VOI,
threshold-based or algorithm-based [104], while TLG incorporates both [ 18F]FDG uptake and size of the tumor, also
known as whole metabolic burden of the tumor [105]. The
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Table 2  Summary of relevant signs of immune activation and their significance during ICIs
Study

Tumor type

ICI type

Number
Metrics
of patients of immune
activation

Conclusion

Wong et al. [39]

Melanoma

Ipi (50)

90

SLR

Prigent et al. [81]

Melanoma

29

SLR
BLR

Sachpekidis et al. [82] Melanoma

Nivo (19)
Pembro (9)
Nivo + ipi (1)
Ipi

Baseline SLR > 1.1 is detrimental
Only for Ipi
Increase > 25%
of SLRmean at 3 months is detrimental

41

Seban et al. [83]

Melanoma

Anti-PD-1

55

Poor performance
of spleen metabolism in predicting clinical
benefit
TMTV* (> 25cm3), SLR (> 0.77) and BLR*
(> 0.79) correlated with shorter survival

Seban et al. [84]

NSCLC

SUVmean, SUVmax, K1, k3,
Ki, FD
SLR
BLR
TMTV
TMTV
TMTV
BLR
SLR

-Muc-M: increased SUVmax associated with
shorter OS
- Cut-M: increased TMTV and increased
BLR independently associated with shorter
OS, shorter PFS

Seban et al. [85]

Nivo
Pembro
Atezo
Melanoma
Anti-PD-1 (45)
(Muc-M:24Cut-M:32) Ipi (11)

80
56

TMTV > 75 cm3 associated with shorter OS

*Remaining significant in a multivariable analysis

as the EANM/EARL program, one of the international harmonization programs aiming at using [ 18F]FDG PET/CT as
a quantitative imaging biomarker [98, 103].

Documentation and reporting
General recommendations for [18F]FDG PET/CT documentation and reporting are available in the EANM guideline
for tumor imaging [98] and SNMMI procedure standards
[99]. Special considerations when dealing with ICIs are
highlighted in the following.
Clinical information
The clinical history of the patient should be briefly summarized, including relevant diagnostic tests and prior
imaging findings. The type and number of cycles of ICIs
must be specified, including the date of the most recent
administration. Concomitant drug and treatments potentially impacting [18F]FDG uptake should be listed. This
particularly includes metformin to avoid misinterpreting
increased colonic uptake as evidence of immunotherapyrelated colitis [109]
Technical Details
Details of the administered activity, uptake interval, scanner used and blood glucose level should be recorded to
allow these to be preferably emulated or, at least, compared for follow-up scans.
Description of the findings

Imaging findings should be described in a logical manner,
preferably following relevance over clinical indication.
Findings may be grouped by significance, TNM staging
or described by body region. For important [ 18F]FDG
findings, the location, extent and intensity of [ 18F]FDG
uptake should be described, as well as the relevant morphological findings on CT.
Target lesions should be identified following the indications of the chosen metabolic response criteria (Table 1)
and reported, including longest diameter on axial view
and SUV/SUL parameters (i.e., max, peak). In case of
tumor response assessment, the pattern of metabolic
response criteria used for the computation must be specified and documented.
Comparison of current findings with prior scans and other
comparative imaging, when available, must be performed
and reported.
The appearance, extent, severity and variation over
time of the irAEs and other signs of immune activation
(Tables 2, 3, and 4) must be described, preferably in a
separate section of the report [34, 78, 110, 111].
Impression/conclusions
According to the clinical indication and timing, the conclusive remarks must be reported. Tumor extent or staging, treatment metabolic response and most relevant irAEs
must be clearly stated. The complex nature of immune
response seen with [18F]FDG PET/CT should be taken
into consideration when performing conclusive remarks,
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Table 3  Immune-related
adverse events in patients with
cancer treated with immune
checkpoint inhibitors classified
according to organ distribution
and incidence [92–97]
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Organ involved

Related irAEs

Overall incidence

Dermatological

Alopecia areata/universalis
Dermatitis herpetiforme
Erythema multiforme
Granuloma annulare
Lichen planopilaris/planus/lichenoid dermatitis
Panniculitis/erythema nodosum
Pemphigoid/pemphigus
Psoriasis
Pyoderma gangrenosum
Sweet syndrome
Vitiligo
Stevens-Johnson syndrome
Bullous pemphigoid
DRESS symptoms
Acute generalized exanthematous pustulosis
Dermatomyositis
Adrenalitis
Autoimmune diabetes mellitus
Hyperparathyroidism/hypoparathyroidism (and
hypocalcemia)
Hypogonadism
Hypophysitis
Thyroiditis
Insulitis (leading to IDDM)
Enterocolitis
Hepatitis
Lymphocytic gastritis
Pancreatitis
Interstitial lung disease
Pneumonitis
Sarcoidosis
Pleural effusions
Reactive airway disease
Autoimmune myocarditis
Myocardial fibrosis
Autoimmune pericarditis
Pericardial effusion
Pericardial tamponade
Cardiomyopathy with Takotsubo-like syndrome
Acute heart failure
Cardiac arrhythmia
Thrombocytopenia
Hemolytic Anemia
Neutropenia
Aplastic Anemia
Pure Red Cell Aplasia
Hemophagocytic Lymphohistiocytosis
Myalgias/Myositis
Dermatomyositis
Arthralgia/polyarthralgia
Arthritis/Enthesitis
Fasciitis/eosinophilic fasciitis
Jaccoud arthropathy
Polymyalgia rheumatica
Psoriatic arthritis
Rheumatoid arthritis
Spondyloarthropathy
Tenosynovitis

44–68% (anti-CTLA-4)
37–42% (anti-PD-1)
58–71% (combination therapy)

Endocrine

Gastrointestinal

Pulmonary

Cardiac

Hematological

Musculo-skeletal

13

1–3.9% (anti-CTLA-4)
0.5–10% (anti-PD-1)
7.7–20% (combination therapy)

10–25% (anti-CTLA-4)
1–5% (anti-PD-1)
14–22% (combination therapy)
3.8% (anti-PD-1)
9.6% (combination therapy)

0.5% (anti-PD-1)
2.4% (combination therapy)

0.5% (anti-CTLA-4)
4.1% (anti-PD-1)
4.7% (anti-PD-L1)

1–23% (anti-CTLA-4)
2–26% (anti-PD-1 or anti-PD-L1)
9–43% (combination therapy)
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Organ involved

Related irAEs

Overall incidence

Neurological

Aseptic meningitis
Encephalitis
Cranial nerve involvement
Motor neuropathy
Myasthenia gravis
Neuromyelitis optica spectrum disorders
Polyneuropathies
Polyradiculopathies
Systemic
- Antiphospholipid syndrome
- Lupus
- Sarcoidosis
- Sicca syndrome/Sjögren syndrome
- Systemic sclerosis
- Vasculitis
Renal
- Acute tubulointerstitial nephritis/renal
tubular acidosis
- Glomerulonephritis
Ocular
- Conjunctivitis
- Episcleritis/scleritis
- Orbital inflammation
- Uveitis

3.8% (anti-CTLA-4)
6% (anti-PD-1)
12% (combination therapy)

Other

with serial measurements and clinical response to be
correlated. Ideally, there should be a focus on findings
of clinical significance, particularly with respect to any
additional diagnostic studies or subsequent scanning that
might be required to clarify or confirm, for instance, the
impression of disease progression (Table 4). Decisions
based on the scan findings alone may be less accurate.
Direct communication
In addition to inclusion in the report conclusion, any
significant abnormalities and severe irAEs [37, 39, 78]
should be verbally communicated to the appropriate
healthcare provider, in order to optimize patient management and avoid treatment delays that otherwise might
result in significant morbidity or mortality. Reporting of
abnormalities requiring urgent attention should be consistent with the policy of the interpreting physician’s local
organization and the pathway for verbal communication.
Additional remarks
Taking into consideration that therapy assessment of
cancer patients receiving ICIs (i) is often made in the
context of busy PET centers and therefore should use
user-friendly and reliable PET metrics, (ii) a consensus
on treating patients beyond disease progression has been
reached in certain tumor types and (iii) [18F]FDG PET/
CT for assessment of immunotherapy is a dynamic field
of research, these guidelines will provide recommendations on the use of the most clinically validated criteria,
with metrics to be gathered for future pooled multicentric
research. Participation of PET readers in tumor boards

0.6–5% (monotherapy)
10–12% (combination therapy)

is crucial for patient care. Furthermore, [ 18F]FDG PET
should be included in prospective randomized clinical
trials in order to determine whether [18F]FDG PETbased response assessment can predict the effectiveness
of a specific drug regimen more accurately than response
assessment by RECIST. It should be recognized that the
use of PET may alter the rate of detecting irAEs compared to that previously identified in routine clinical care
and may impact both subsequent treatments that might be
administered for these complications and the longer-term
consequences.
The implementation of artificial intelligence (AI) for
image analysis with the development of dedicated algorithms for PET image segmentation as well as AI-based
evaluation of follow-up studies will facilitate therapy
monitoring with [18F]FDG PET–CT in future [112–114].
Additionally, the translation of dedicated tracers into
clinical routine, like labeled T cells, or labeled PD-1 or
PD-L1 antibodies will provide complementary information to [18F]FDG and improve prediction to immunotherapy response [115].

Checklist
Table 4 highlights the checklist of requirements for patients
with solid tumors treated with ICI.
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Table 4  Checklist of requirements and recommendations to consider when approaching [18F]FDG PET/CT imaging during treatment with ICIs
CHECKLIST
HISTORY

THERAPY RESPONSE

ASSESSING IMMUNE ORGANS
MANIFESTATIONS OF IMMUNERELATED ADVERSE EVENTS

Type of immunomodulatory treatment
• ICI: e.g., anti-CTLA-4, anti-PD-1/PD-L1 or combination
• Intratumoral immunotherapies
• Cell-based immunotherapies
Number of cycles received and date of the last injection
If intratumoral administration the site of injection
Prior lines of treatment
If combination treatment, the type of treatment or, in case of radiation, the site of irradiation
Clinical symptoms suggesting immune-related adverse events
For diabetic patients, check whether drugs likely to mimic colitis (biguanides) have been given
Previous or ongoing use of corticosteroids and antibiotics should be noted
Response of target lesion(s)
If the appearance of new lesions:
• The number of new anatomical sites and the number of new lesions
• Could new lesions be explained by other processes such as sarcoidosis or other irAES?
• If new nodal sites
○ located in the drainage area of the main tumor?
○ In a distribution suggestive of sarcoid-like lymphadenopathy
If possible, include MTV/TLG at baseline and subsequent studies
If there is doubt whether there is progression or pseudoprogression, especially on the first posttreatment evaluation and a confirmatory follow-up [18F]FDG PET/CT study in > 4 weeks
later in the setting of clinical stability or biopsy should be recommended
Report spleen-to-liver ratio
Different ICIs have differing side-effect profiles (e.g., colitis is more common in anti-CTLA-4
and pneumonitis more common in anti-PD-1/PD-L1)
Sarcoidosis can have variable presentations and can involve lymph nodes and other organs
Increased bone marrow activity and inversion of spleen-to-liver [18F]FDG uptake ratio may
support systemic immune response
If available comparison with baseline study, it is critical to monitor the metabolic activity
within the organs
Preferably, the brain should be included, [18F]FDG uptake in the pituitary gland should be
checked and compared it to the baseline study
When immune-related adverse events are shown on [18F]FDG PET/CT check patient’s recovery on subsequent studies
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